Straits Times Index
3,303.02 -11.03 (-0.33%) Nikkei
39,174.74 +105.06 (+0.27%) Hang Seng
19,237.27 -398.95 (-2.03%) FTSE 100
8,424.20 +3.94 (+0.05%) Bitcoin USD
71,294.80 +4,614.52 (+6.92%) CMC Crypto 200
1,529.92 +175.51 (+12.95%)
GILD May 2024 64.000 call
| Previous close | 2.5500 |
| Open | 2.5000 |
| Bid | 2.9300 |
| Ask | 4.2000 |
| Strike | 64.00 |
| Expiry date | 2024-05-31 |
| Day's range | 2.5000 - 2.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 22 |
BenzingaGilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study. The ASSURE study is an open-label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis (PBC) who have already participated in other PBC clinical trials of seladelpar. The study is currently enrolling up to 500 people. Also Read: Gilead’s Aggressive Push Beyond HIV Treatments
Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu
Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
